Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Thompson, A; Sorensen, PS; Montalban, X; Cook, S; Goodkin, D; Filippi, M; Kappos, L; Cohen, J; Ebers, G; Cutter, G; Fazekas, F; Barkhof, F; Miller, A; Brooks, BR; Noseworthy, J; Lucchinetti, C; Weinshenker, B.
Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis - Question and answer session.
MULT SCLER. 2004; 10 Suppl 1(1): S62; discussion 62-S62; discussion 64.
Doi: 10.1191/1352458504ms1033oa
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - therapeutic use
- Europe - therapeutic use
- Humans - therapeutic use
- Interferon-beta - therapeutic use
- Multiple Sclerosis, Chronic Progressive - drug therapy
- Pilot Projects - drug therapy